REBLOZYL

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Spain, Turkey.

Active ingredients

The drug REBLOZYL contains one active pharmaceutical ingredient (API):

1	Luspatercept UNII AQK7UBA1LS - LUSPATERCEPT
	Luspatercept, an erythroid maturation agent, is a recombinant fusion protein that binds selected transforming growth factor-β (TGF-β) superfamily ligands. By binding to specific endogenous ligands (e.g. GDF-11, activin B) luspatercept inhibits Smad2/3 signalling, resulting in erythroid maturation through differentiation of late-stage erythroid precursors (normoblasts) in the bone marrow.
	Read more about Luspatercept

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REBLOZYL Powder for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
REBLOZYL Powder for solution for injection / infusion	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B03XA06		B Blood and blood forming organs → B03 Antianemic preparations → B03X Other antianemic preparations → B03XA Other antianemic preparations
Discover more medicines within B03XA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02505541, 02505568
EE	Ravimiamet	1821912, 1821923
ES	Centro de información online de medicamentos de la AEMPS	1201452001, 1201452002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	473722, 598825
FR	Base de données publique des médicaments	60175591, 62508169
IL	מִשְׂרַד הַבְּרִיאוּת	8784, 8785
IT	Agenzia del Farmaco	048905018, 048905020
LT	Valstybinė vaistų kontrolės tarnyba	1090725, 1090726
NL	Z-Index G-Standaard, PRK	203971, 203998
PL	Rejestru Produktów Leczniczych	100438911, 100438928
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67355001, W67356001
TR	İlaç ve Tıbbi Cihaz Kurumu	8699726269406, 8699726269505
US	FDA, National Drug Code	59572-711, 59572-775